AstraZeneca ends lung cancer drug trial: What to know
AstraZeneca has ended a phase 3 clinical trial of the drug volrustomig for the treatment of metastatic non-small cell lung cancer. The trial was specifically evaluating the drug in combination with chemotherapy compared to pembrolizumab and chemotherapy in metastatic non-small cell lung cancer patients whose PD-L1 scores were less than 50%, according to an Aug. […] The post AstraZeneca ends lung cancer drug trial: What to know appeared first on Becker's Hospital Review | Healthcare N...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.